A growing number of U.S veterans, desperate to treat PTSD, are turning to psychedelics. They're headed to other countries, ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...

In a concerning development for public health, the Food and Drug Administration (FDA) has issued a critical warning about ...

Let’s cut to the chase: erectile dysfunction (ED) is a common issue, but it’s not the end of the world. Not even on Valentine ...

The EMA’s hu­man med­i­cines com­mit­tee rec­om­mend­ed 114 med­i­cines for ap­proval in 2024, mark­ing the high­est num­ber of pos­i­tive opin­ions is­sued in 15 years ...

Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Is Hims & Hers stock in trouble, or is this just a bump in the road for what could still ...

Hims & Hers makes it easy for patients to buy a growing list of prescription medications on its website ... service to help treat areas such as erectile dysfunction and hair loss, which are ...

Before the advent of medications, individuals with these more extreme symptoms often found themselves stuck—unable to engage meaningfully in therapy or, in many cases, requiring long-term ...

First-in-class drugs are therapies that utilize novel mechanisms of action, offering new approaches to challenging diseases. In 2024, the U.S. Food and Drug Administration (FDA) approved 50 new ...

OS Ther­a­pies is mov­ing ahead with plans for an ac­cel­er­at­ed ap­proval path­way af­ter its off-the-shelf can­di­date for peo­ple who have had surgery to treat os­teosar­co­ma … ...